Physician profile
John Robert Webster
NPI 1093240178
$1,933.01
in general payments reported to CMS, 2019-2025
27 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.36 · 2022: $117 · 2023: $490 · 2024: $837 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.69 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $307.46 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Viiv Healthcare Company | $202.75 | 2024-2025 | Dovato, Apretude |
| Abbott Laboratories | $178.61 | 2024 | Freestyle Libre 3 |
| Insulet Corporation | $122.00 | 2022-2024 | Omnipod |
| Amgen INC. | $120.24 | 2024-2025 | Tepezza |
| Paratek Pharmaceuticals, INC. | $101.66 | 2024-2025 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $84.89 | 2023-2024 | Gvoke Hypopen |
| Medtronic, INC. | $77.78 | 2023-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Glaxosmithkline, LLC. | $76.00 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Recordati_rare_diseases_inc. | $74.62 | 2024 | Isturisa, Signifor Lar |
| Corcept Therapeutics | $70.36 | 2021 | |
| Mannkind Corporation | $52.84 | 2022-2023 | Afrezza |
| Astellas Pharma US INC | $50.67 | 2023-2024 | Cresemba |
| Janssen Biotech, INC. | $49.34 | 2022-2023 | Erleada |
| Tandem Diabetes Care, INC. | $44.48 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.06 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.89 | 2024 | |
| Horizon Therapeutics Plc | $37.30 | 2022-2023 | Tepezza |
| Lilly USA, LLC | $30.97 | 2023 | Mounjaro |
| Dexcom, INC. | $29.82 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $28.89 | 2024 | Inspire |
| Abbvie INC. | $25.83 | 2023 | Synthroid |
| Baxter Healthcare | $25.40 | 2024 | Hillrom - Monarch Airway Clearance System |
| Hologic Sales and Service, LLC | $17.70 | 2023 | Aptima |
| Cequr Corporation | $15.28 | 2024 | Cequr Simplicity |
| Astrazeneca Pharmaceuticals LP | $14.43 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $13.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.